An exploration of LAF-bTMB as a predictor for the efficacy of immunotherapy combined with chemotherapy in non-small cell lung cancer.

ABSTRACT:

Background

Immune checkpoint inhibitor (ICI) combined with chemotherapy is one of the standards of care for advanced non-small cell lung cancer (NSCLC) without driver mutations. However, the biomarker of combination therapy is still unknown. Although previous studies have confirmed that low allele frequency adjusted blood-based tumor mutational burden (LAF-bTMB) is associated with the efficacy of ICI monotherapy, there has been no report on the correlation between the efficacy of LAF-bTMB and ICI combined chemotherapy. This study aimed to explore whether LAF-bTMB can be used as a predictive biomarker for the efficacy of immunotherapy combined with chemotherapy in advanced NSCLC.

Methods

This study enrolled patients diagnosed with advanced NSCLC and who received ICI combined

SUBMITTER: Zhang S 

PROVIDER: S-EPMC9715764 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature